Results 41 to 50 of about 4,930 (158)

Drug-Induced Urinary Stone of Atazanavir Incidentally Found in an Asymptomatic Patient: A Case Report

Case Reports in Urology, 2023
A HIV-infected female treated with a combination of emtricitabine/elvitegravir/tenofovir since 2017 presented an acute renal failure during her hospitalization for a SARS-CoV2 pneumonia.
Maëlle Plawecki, Marie Bistoquet, Pierre-Edouard Grillet, Nicolas Abdo, Jean-Sébastien Souweine, Jean-Paul Cristol   +5 more
doaj   +1 more source

Population Pharmacokinetics of Dolutegravir in Plasma and Cerebrospinal Fluid in Adults Living With HIV

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 10, October 2026.
ABSTRACT Characterizing dolutegravir penetration into the central nervous system is important for optimizing human immunodeficiency virus treatment outcomes, yet population‐specific pharmacokinetic data describing cerebrospinal fluid disposition and equilibration kinetics remain lacking.
Mohammed W. Ali, Sam Nightingale, Tracy Kellermann, John Joska, Alan Winston, Saye Khoo, Joseph F. Standing, Eric H. Decloedt, Ahmed A. Abulfathi   +8 more
wiley   +1 more source

From protease inhibitors to integrase strand transfer inhibitors: the evolution of HIV drug resistance management

Zhongguo linchuang yanjiu
Antiretroviral therapy (ART) has significantly improved the prognosis of HIV/AIDS patients and has become an important global strategy for the prevention and control of AIDS.
HU Zhiliang, YANG Yongfeng
doaj   +1 more source

New onset type 2 diabetes mellitus risks with integrase strand transfer inhibitors-based regimens: A systematic review and meta-analysis

Metabolism Open, 2023
Objectives: The development of diabetes mellitus (DM) in patients taking integrase strand transfer inhibitors (INSTIs) has raised concerns. It's critical because, in most guidelines, INSTIs are the preferred third agent at first-line regimens. This study
Violet Dismas Kajogoo, Wondwossen Amogne, Girmay Medhin   +2 more
doaj   +1 more source

HIV Viral Rebound Due to a Possible Drug–Drug Interaction between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide and Calcium-Containing Products: Report of 2 Cases

Journal of the International Association of Providers of AIDS Care, 2019
Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) is a potent fixed-dose, once-daily regimen for HIV-1 treatment and has rare emergence of drug resistance.
S. Lena Kang-Birken PharmD, Dena El-sayed MD, John Prichard MD   +2 more
doaj   +1 more source

Curcumin enhances elvitegravir concentration and alleviates oxidative stress and inflammatory response

Scientific Reports, 2023
In this study, we investigated the potential of using curcumin (CUR) as an adjuvant to enhance the delivery of antiretroviral drug elvitegravir (EVG) across the BBB, and alleviate oxidative stress and inflammatory response, which are the major hallmark ...
Sandip Godse, Lina Zhou, Namita Sinha, Sunitha Kodidela, Asit Kumar, Udai P. Singh, Santosh Kumar   +6 more
doaj   +1 more source

Temporal shifts in antiretroviral therapy regimens and metabolic outcomes in people living with HIV: A systematic review and meta‐analysis

HIV Medicine, Volume 27, Issue 9, Page 1399-1420, September 2026.
Abstract Introduction Antiretroviral therapy (ART) for people living with HIV has led to dramatically reduced mortality and improved life expectancy. This achievement is accompanied by a higher risk for metabolic and other non‐communicable diseases. The role and contribution of various ART regimens to adverse metabolic outcomes are not fully understood.
Melani Ratih Mahanani, Myo Chit, Sophie Mohr, Elisenda Cama i Gibernau, Svetlana Hetjens, Volker Winkler, Hans‐Michael Steffen, Florian Neuhann   +7 more
wiley   +1 more source

HIV-1 escape in the central nervous system on elvitegravir-based antiretroviral therapy

, 2019
International audienceIntegrase inhibitors are increasingly used in combined antiretroviral therapy (ART) because of their high efficacy in inhibiting HIV replication and favourable tolerance profile.
Metsu, David, Delobel, Pierre, Martin-Blondel, Guillaume, Izopet, Jacques, Raymond, Stéphanie, Gandia, Peggy, Guerveno, Claire   +6 more
core   +1 more source

DEVELOPMENT AND VALIDATION OF UV SPECTROPHOTOMETRIC METHOD FOR THE ESTIMATION OF ELVITEGRAVIR (EVG) IN BULK AND PHARMACEUTICAL FORMULATIONS [PDF]

, 2020
A simple, rapid, precise and economical spectrophotometric method has been developed for quantitative analysis of Elvitegravir (EVG) in manufactured tablet formulation. The stock solution and subsequent dilution of Elvitegravir was done in methanol.
Kiran B Aher, S R Chaudhari, Swati S Pardhi, Girija B Bhavar   +3 more
core  

Targeting Human Immunodeficiency Virus Integrase Beyond the Active Site: The Discovery and Development of Allosteric Integrase Inhibitors

ChemMedChem, Volume 21, Issue 16, 27 August 2026.
Human immunodeficiency virus (HIV) allosteric integrase inhibitors (ALLINIs) offer a vital alternative to standard therapies by targeting noncatalytic sites. By inducing aberrant integrase multimerization, they disrupt viral maturation. This review explores their medicinal chemistry evolution, detailing structural insights, structure–activity ...
Francesco Saccoliti, Elisa Patacchini, Emanuele Cara, Laura Zarbo, Antonella Messore, Aurora Albano, Giuseppe Ruggieri, Valentina Noemi Madia, Luigi Scipione, Roberta Costi, Roberto Di Santo   +10 more
wiley   +1 more source